Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104


The arginine metabolome in acute lymphoblastic leukemia can be targeted by the pegylated-recombinant arginase I BCT-100.

De Santo C, Booth S, Vardon A, Cousins A, Tubb V, Perry T, Noyvert B, Beggs A, Ng M, Halsey C, Kearns P, Cheng P, Mussai F.

Int J Cancer. 2018 Apr 1;142(7):1490-1502. doi: 10.1002/ijc.31170. Epub 2017 Dec 26.


Recombinant human arginase induces apoptosis through oxidative stress and cell cycle arrest in small cell lung cancer.

Xu S, Lam SK, Cheng PN, Ho JC.

Cancer Sci. 2018 Nov;109(11):3471-3482. doi: 10.1111/cas.13782. Epub 2018 Oct 6.


Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target.

Mussai F, Egan S, Higginbotham-Jones J, Perry T, Beggs A, Odintsova E, Loke J, Pratt G, U KP, Lo A, Ng M, Kearns P, Cheng P, De Santo C.

Blood. 2015 Apr 9;125(15):2386-96. doi: 10.1182/blood-2014-09-600643. Epub 2015 Feb 20.


Pegylated arginase I: a potential therapeutic approach in T-ALL.

Hernandez CP, Morrow K, Lopez-Barcons LA, Zabaleta J, Sierra R, Velasco C, Cole J, Rodriguez PC.

Blood. 2010 Jun 24;115(25):5214-21. doi: 10.1182/blood-2009-12-258822. Epub 2010 Apr 20.


Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest.

Lam TL, Wong GK, Chong HC, Cheng PN, Choi SC, Chow TL, Kwok SY, Poon RT, Wheatley DN, Lo WH, Leung YC.

Cancer Lett. 2009 May 8;277(1):91-100. doi: 10.1016/j.canlet.2008.11.031. Epub 2009 Jan 12.


Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts.

Lam SK, Li YY, Xu S, Leung LL, U KP, Zheng YF, Cheng PN, Ho JC.

Respir Res. 2017 May 2;18(1):80. doi: 10.1186/s12931-017-0564-3.


Vincristine could partly suppress stromal support to T-ALL blasts during pegylated arginase I treatment.

Kwong-Lam F, Chi-Fung CG.

Exp Hematol Oncol. 2013 Apr 10;2(1):11. doi: 10.1186/2162-3619-2-11.


Effects of the combined arginase and canavanine treatment on leukemic cells in vitro and in vivo.

Vovk OI, Chen OI, Igumentseva NI, Senchuk OY, Barska ML, Sybirna NO, Stasyk OV.

Ukr Biochem J. 2016 Mar-Apr;88(2):45-55. doi: 10.15407/ubj88.02.045.


Endogenous arginase 2 as a potential biomarker for PEGylated arginase 1 treatment in xenograft models of squamous cell lung carcinoma.

Lam SK, Yan S, Xu S, U KP, Cheng PN, Ho JC.

Oncogenesis. 2019 Feb 26;8(3):18. doi: 10.1038/s41389-019-0128-0.


Bioengineered arginase I increases caspase-3 expression of hepatocellular and pancreatic carcinoma cells despite induction of argininosuccinate synthetase-1.

Glazer ES, Kaluarachchi WD, Massey KL, Zhu C, Curley SA.

Surgery. 2010 Aug;148(2):310-8. doi: 10.1016/j.surg.2010.03.022. Epub 2010 May 13.


Cytotoxicity of human recombinant arginase I (Co)-PEG5000 in the presence of supplemental L-citrulline is dependent on decreased argininosuccinate synthetase expression in human cells.

Agrawal V, Woo JH, Mauldin JP, Jo C, Stone EM, Georgiou G, Frankel AE.

Anticancer Drugs. 2012 Jan;23(1):51-64. doi: 10.1097/CAD.0b013e32834ae42b.


Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma.

De Santo C, Cheng P, Beggs A, Egan S, Bessudo A, Mussai F.

J Hematol Oncol. 2018 May 18;11(1):68. doi: 10.1186/s13045-018-0612-6.


Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo.

Miraki-Moud F, Ghazaly E, Ariza-McNaughton L, Hodby KA, Clear A, Anjos-Afonso F, Liapis K, Grantham M, Sohrabi F, Cavenagh J, Bomalaski JS, Gribben JG, Szlosarek PW, Bonnet D, Taussig DC.

Blood. 2015 Jun 25;125(26):4060-8. doi: 10.1182/blood-2014-10-608133. Epub 2015 Apr 20.


Anti-tumor efficacy of a recombinant human arginase in human hepatocellular carcinoma.

Chow AK, Ng L, Sing Li H, Cheng CW, Lam CS, Yau TC, Cheng PN, Fan ST, Poon RT, Pang RW.

Curr Cancer Drug Targets. 2012 Nov 1;12(9):1233-43. Review.


Molecular basis and current strategies of therapeutic arginine depletion for cancer.

Fultang L, Vardon A, De Santo C, Mussai F.

Int J Cancer. 2016 Aug 1;139(3):501-9. doi: 10.1002/ijc.30051. Epub 2016 Apr 15. Review.


Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.

Shi PJ, Xu LH, Lin KY, Weng WJ, Fang JP.

J Hematol Oncol. 2016 Feb 18;9:12. doi: 10.1186/s13045-016-0241-x.


Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia.

Gang EJ, Hsieh YT, Pham J, Zhao Y, Nguyen C, Huantes S, Park E, Naing K, Klemm L, Swaminathan S, Conway EM, Pelus LM, Crispino J, Mullighan CG, McMillan M, Müschen M, Kahn M, Kim YM.

Oncogene. 2014 Apr 24;33(17):2169-78. doi: 10.1038/onc.2013.169. Epub 2013 Jun 3.


Recombinant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis.

Lam TL, Wong GK, Chow HY, Chong HC, Chow TL, Kwok SY, Cheng PN, Wheatley DN, Lo WH, Leung YC.

Pigment Cell Melanoma Res. 2011 Apr;24(2):366-76. doi: 10.1111/j.1755-148X.2010.00798.x. Epub 2010 Dec 6.


The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma.

Thongkum A, Wu C, Li YY, Wangpaichitr M, Navasumrit P, Parnlob V, Sricharunrat T, Bhudhisawasdi V, Ruchirawat M, Savaraj N.

Int J Mol Sci. 2017 Jun 1;18(6). pii: E1175. doi: 10.3390/ijms18061175.

Supplemental Content

Support Center